Loading…
← CockpitCompetitor Analysis › 000423.SZ Dong-E-E-Jiao Co., Ltd. Class AOpen in the cockpit ↗

Dong-E-E-Jiao Co., Ltd. Class A000423.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

China's leading donkey-hide gelatin (Ejiao) maker, selling a traditional tonic product prized for blood and health benefits.

≈ A single-category Chinese heritage tonic brandMomentum leader 92
Mkt cap
$4.99B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$49.2M
20-day average traded
Fwd P/E
17.8×
forward earnings
ROIC−WACC
+51.5 pp
WACC 5.4%
Hurdle
-18 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥52.64
1D-0.1%
1W+8.4%
1M+8.2%
3M-0.1%
6M+0.7%
YTD+7.2%
1Y+10.2%
ATR %2.4%
52w lowhigh9.8% off high

What Dong-E-E-Jiao does

China's leading donkey-hide gelatin (Ejiao) maker, selling a traditional tonic product prized for blood and health benefits.

Sells a premium tonic bought partly as a gift, so brand heritage and the distribution channel matter more than manufacturing. The raw material, donkey hide, is scarce, so its supply and cost are a central lever.

In one line: A single-category Chinese heritage tonic brand.

Products and services

  • Donkey-hide gelatin (Ejiao) blocks
  • Ejiao-based health products
  • Other TCM products

Customers

  • Retail pharmacies
  • Gift/health-product consumers

Where it sits in the supply chain

  • Pharmaceuticals
  • Traditional Chinese medicine
  • Donkey-hide gelatin tonics

What could go right

  • Gifting and tonic-food consumption trends

What could go wrong

  • Donkey-hide raw material scarcity/cost
  • Counterfeit product competition

Moat: narrow (brand, scale). Dominant heritage brand in Ejiao with control over scarce donkey-hide raw material supply.

Headquarters: Liaocheng, Shandong, China · Founded: 1952 · Employees: 4,345

Named competitors

  • Fusen Noble House (Fangboshi Ejiao) private or unlisted
  • Jiuzhitang 000989.SZ

Dong-E-E-Jiao at a glance

Size Dong-E-E-Jiao (000423.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $4.99B, the 465th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥52.64 on 18 Nov 2026.

Performance Over six months the shares gained 0.7%, against -0.2% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 8.1% over the last twelve months (peer median +10.1%); the operating margin is 29.4% (peer median 15.3%).

Valuation It trades at 17.8× forward earnings against a peer median of 20.6× (8th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 51.5 points above its cost of capital (5.4% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026000423.SZ 104Peer median 101
Six months, rebased to 100: Dong-E-E-Jiao against the median of its 20 peers (local-currency closes).

Dong-E-E-Jiao financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.87BCN¥6.64BCN¥6.11BCN¥4.67BCN¥4.00B
Revenue growth—+9%+31%+17%—
Gross profitCN¥5.15BCN¥4.76BCN¥4.14BCN¥3.17BCN¥2.61B
EBITDAn/aCN¥2.10BCN¥1.79BCN¥1.40BCN¥1.04B
Net incomeCN¥1.79BCN¥1.74BCN¥1.56BCN¥1.15BCN¥780M
Free cash flowCN¥1.15BCN¥2.30BCN¥2.85BCN¥1.95BCN¥2.18B
Capital expenditureCN¥320MCN¥82.7MCN¥97.4MCN¥54.5MCN¥45.6M
Total debtCN¥168MCN¥94.0MCN¥38.3MCN¥47.8MCN¥62.9M

Quarterly statements and history in the cockpit →

Dong-E-E-Jiao competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%002603ABVXBHC002317000623LUPIN300146600062600750AUROPHARMA1112002001CIPLA300363600216SUDEEPPHRMJWEL000423.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Dong-E-E-Jiao is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×50×002603BHC002317LUPIN300146600062600750AUROPHARMA1112GRANULES002001CIPLA600216SUDEEPPHRMJWEL000423.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dong-E-E-Jiao is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%002603BHC002317000623LUPIN300146600062600750AUROPHARMA1112GRANULES002001CIPLA600056300363002287600216JWEL000423.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dong-E-E-Jiao is the large dot.

Dong-E-E-Jiao competitors and peer comparison

Head to head with its named competitors (000423.SZ vs 000989.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Dong-E-E-Jiao 000423.SZ$4.99B+1%+8%29%17.8×-3.7%
Jiuzhitang 000989.SZ$1.16B-7%+46%19%22.1×-4.0%

How Dong-E-E-Jiao compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dong-E-E-Jiao against its 20 peers (data as of 18 Nov 2026)
Measure000423.SZPeer medianRank in peer set
1-month return+8.2%-0.5%5th highest of 21
6-month return+0.7%-0.2%10th highest of 21
Distance from 52-week high-9.8%-22.6%6th highest of 21
Revenue growth (TTM)+8.1%+10.1%10th lowest of 20
Operating margin29.4%15.3%3rd highest of 20
Forward P/E17.8×20.6×8th cheapest of 16
Growth the price implies (Req g, 7 yrs)-3.7%0.4%6th least demanding of 19
Growth delivered (Del g)+14.5%+6.1%3rd highest of 19
Hurdle (Req g minus delivered)-18.3 pp-3.0 pp3rd least demanding of 19
ROIC minus cost of capital+51.5 pp+2.6 pphighest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dong-E-E-Jiao 000423.SZChina$4.99B+1%+8%29%17.8×-3.7%+14.5%
Shijiazhuang Yiling Pharmaceutical 002603.SZChina$3.83B-7%+32%21%17.5×-3.9%-2.2%
Abivax ABVX.PAFrance$7.36B-30%n/an/an/an/an/a
Bausch Health Companies BHC.TOCanada$3.27B+66%+10%27%2.0×-14.8%+5.9%
Guangdong Zhongsheng Pharmaceutical 002317.SZChina$3.00B+11%-14%9%91.7×33.8%+5.9%
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%n/a5.0%+1.0%
Lupin LUPIN.NSIndia$9.67B-14%+24%24%21.0×8.8%+13.0%
By-health 300146.SZChina$2.56B-1%+10%11%24.7×4.8%+0.6%
China Resources Double-Crane Pharmaceutical 600062.SSChina$2.35B-14%-1%13%9.3×-9.1%+5.3%
China Resources Jiangzhong Pharmaceutical 600750.SSChina$2.27B+4%-10%24%16.5×-1.9%+11.6%
Aurobindo Pharma AUROPHARMA.NSIndia$11.0B+19%+14%15%22.3×21.1%+6.3%
Health and Happiness (H&H) International 1112.HKHong Kong$2.15B+108%+24%16%13.2×-1.7%+4.4%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%24.8×23.6%+10.6%
Zhejiang NHU 002001.SZChina$11.8B-22%+11%33%9.7×-8.3%+16.7%
Cipla CIPLA.NSIndia$12.2B+1%-1%13%29.1×28.4%+8.1%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%

Questions

Who are Dong-E-E-Jiao's main competitors?
Named competitors: Fusen Noble House (Fangboshi Ejiao) (private or unlisted), Jiuzhitang (000989.SZ). The cockpit's measured peer set (industry) also includes Shijiazhuang Yiling Pharmaceutical (002603.SZ), Abivax (ABVX.PA), Bausch Health Companies (BHC.TO), Guangdong Zhongsheng Pharmaceutical (002317.SZ), Jilin Aodong Pharmaceutical (000623.SZ), Lupin (LUPIN.NS).
Is Dong-E-E-Jiao expensive compared with its peers?
On forward p/e it trades at 17.8× against a peer median of 20.6×, 8th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has Dong-E-E-Jiao stock performed?
Over six months to 18 Nov 2026 the shares returned +0.7% against -0.2% for the median peer; over one year +10.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.